Apogee Therapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 30 Jun 2026
Net Income -$294.4MTTM through 30 Jun 2026
Free Cash Flow -$249MTTM through 30 Jun 2026
Margins
| Current |
|---|
Returns
-5.9%ROE
-5.7%ROA
Balance Sheet Health
Debt / Equity0.00x
Current Ratio32.59x
Net Debt-$1.1Bnet cash position
Cash & Equivalents$105.6M
Quality Metrics
Altman Z-Score75.94
Piotroski F-Score1 / 9
Earnings-Beat Rate75.0%
Multi-Year Trend
Diluted EPS-$4.34TTMFY2025: $-4.22
Dividend
No dividend
Capital Allocation
R&D Spend$240.7M
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.